MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Revenue of MediWound Ltd. (MDWD)
Revenue in 2023 (TTM): $18.69 M
According to MediWound Ltd.'s latest financial reports the company's current revenue (TTM) is $18.69 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of MediWound Ltd.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $18.69 M | $2.95 M | $-14,198,000 | $-6,531,000 | $-6,716,000 |
| 2022 | $26.5 M | $13.17 M | $-9,331,000 | $-19,521,000 | $-19,599,000 |
| 2021 | $23.76 M | $8.77 M | $-9,983,000 | $-13,524,000 | $-13,551,000 |
| 2020 | $21.76 M | $7.55 M | $-7,750,000 | $-9,276,000 | $-9,601,000 |
| 2019 | $31.79 M | $19.94 M | $5.64 M | $2.07 M | $3.72 M |
| 2018 | $3.4 M | $1.31 M | $-3,383,000 | $-5,665,000 | $-1,057,000 |
| 2017 | $2.5 M | $918 K | $-13,120,000 | $-14,533,000 | $-22,149,000 |
| 2016 | $1.56 M | $-600,000 | $-19,566,000 | $-18,885,000 | $-18,885,000 |
| 2015 | $601 K | $-1,918,000 | $-20,724,000 | $-21,671,000 | $-22,088,000 |
| 2014 | $259 K | $-2,526,000 | $-16,270,000 | $-18,875,000 | $-18,875,000 |
| 2013 | $ | $ | $-4,860,000 | $-8,501,000 | $-15,351,000 |
| 2012 | $ | $ | $-2,469,000 | $11.99 M | $10.94 M |
| 2011 | $ | $ | $-4,096,000 | $-4,819,000 | $-6,169,000 |